We use cookies for a better user experience. Read our Privacy Policy

I Agree

Cardiovascular Drugs Market

Cardiovascular Drugs Market (Drug Class - Anti hyperlipidemics, Anti-hypertensives, Anti-coagulants, Anti-fibrinolytics, Anti-arrhythmic; Distribution Channels - Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system. The global cardiovascular drugs market was valued approximately US$ 80.0 Bn in 2016 and is anticipated to register CAGR of over 1.0% from 2017 to 2025 to reach value of approximately US$ 91.0 Bn by 2025. Drug classes used to treat cardiovascular indications such as hyperlipidemia, hypertension are likely to fuel expansion of the global cardiovascular drugs market from 2017 to 2025.

Cardiovascular diseases are one of the leading causes of death worldwide. According to American Heart Association, in 2015, approximately 41.5% of the U.S. population was suffering from some form of cardiovascular disease, it is further estimated that this prevalence is likely to increase to 45% by 2035. Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (47%) have at least one of these three risk factors. To treat the diseases, key players are investing in to develop new drugs with better efficacy and less side effects. Launch of PCSK9 inhibitors (Praluent) for treating hyperlipidemia in 2016 is likely to fuel expansion of anti-hyperlipidemia drugs market segment by 2025 augmenting global cardiovascular drugs market. However, recent expiry of patent exclusivity of blockbuster cardiovascular drugs has led to plethora of generic drugs which is likely to hamper global cardiovascular drugs market.

cardiovascular-drugs-market.jpg

There are many unmet needs in global cardiovascular drugs market which create huge opportunities for existing players and new entrants in global market. Biologics provide ample opportunities for players operating in the global cardiovascular drugs market. Recent developments in biologic cardiovascular drugs such as Pfizer’s PCSK9 inhibitor, Esperion Therapeutics’ novel LDL-lowering drug ETC-1002 and Merck’s CETP inhibitor anacetrapib, uncovers the potential of these drugs. Blockbuster drugs are losing their patent exclusivity which has set a trend to introduce generics in market by local as well as international players. For instance, Crestor launched by Astrazeneca and indicated for the treatment of hyperlipidemia, lost patent in early 2016 and in April 2016, the U.S. FDA approved first generic to this drug to Watson Pharmaceuticals Inc.

The global cardiovascular drugs market has been segmented on the basis of drug class, indication, distribution channel and geography. Among drug class, anti-clotting agents segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by anti-hyperlipidemia segment. Introduction of new anti-hyperlipidemia drug such as PCSK9 Inhibitor (Praluent) and increasing incidences of hyperlipidemia is likely to propel expansion of the segment. Among indications, hypertension was the leading revenue generating segment in 2016 and it is likely to continue its dominance during the forecast period. Arrhythmia segment of indication is likely to lose its market share during the forecast period owing to shift of preference from anti-arrhythmia drugs to advanced implantable cardiovascular devices such as pacemakers. Among various distribution channels, retail pharmacies was the leading distribution channel in 2016 and is likely to account for leading share during the forecast period.

Geographically, North America captured lion’s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives  for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.

Key companies operating in the global cardiovascular drugs market and profiled in the report include AstraZeneca plc., Bayer AG, Merck & Co., Inc., Sanofi, Pfizer, Inc., Eli Lilly & Company among others. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base and garner market share. For instance, in December 2015, AstraZeneca acquired ZS pharma which added pipeline biological drug for chronic heart failure to AstraZeneca’s existing cardiovascular drugs pipeline. In another instance, in 2016, Sanofi launched new cardiovascular drug Praluent for treatment of hyperlipidemia.

Alarming Rise in the Cases of Cardiovascular Diseases and Disorders to Propel the Growth Opportunities across the Cardiovascular Drugs Market

Cases related to cardiovascular disorders and diseases have increase manifold over the years. The growing prevalence of cardiovascular diseases has resulted in the formation of novel drugs and formulations for rapid treatment. The growing demand for such products will bring immense growth opportunities for the cardiovascular drugs market during the assessment period of 2017-2025.

  • Cardiovascular diseases include coronary heart disease, hyperlipidemia, myocardial infarction, disorders of the blood vessels, and others. The drugs used to treat all these diseases and disorders are known as cardiovascular drugs. The heightening popularity of these drugs for quick relief from a number of diseases will bring immense growth prospects across the forecast period.
  • Heart disease is the leading cause of death in the United States as per the study by the Centers for Disease Health and Prevention (CDC),. The CDC also estimates that one individual in the United States dies every second from cardiovascular disease. These alarming statistics raise concerns about the need for controlling the menace. Thus, all these aspects are laying a red carpet of growth for the cardiovascular drugs market.
  • The players in the cardiovascular drugs market are always involved in research and development activities. They invest heavily in these activities for exploring novel insights and discovering new formulations, ultimately leading to a boost in revenues.
  • The players also indulge in strategic collaborations. The collaborations assist in propelling the influence of the players in the cardiovascular drugs market. Mergers, acquisitions, collaborations, and joint ventures form the foundation of growth. Thus, all these factors help in increasing the growth rate of the cardiovascular drugs market.
  • The COVID-19 pandemic has a little negative impact on the cardiovascular drugs market. The healthcare and pharmaceuticals sector was exempted from the strict lockdown restrictions and hence, the cardiovascular drugs market was protected from disruptions.

The global cardiovascular drugs market has been segmented as follows:

Drug Class

  • Renin-Angiotensin System Blockers
    • ACE Inhibitors
    • Angiotensin Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Anti-Clotting Agents
    • Anti-Coagulants
    • Platelet Aggregation Inhibitors
  • Antihyperlipidemics
  • Other Antihypertensive
  • Calcium Channel Blockers
  • Others

Indication

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Peripheral Artery Disease
  • Arrhythmia
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • GCC Region
    • Israel
    • Rest of Middle East & Africa
Cardiovascular Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global CVD Market

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Class Definition
            4.1.2. Industry Developments
     4.2. Overview
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunities
     4.5. Global CVD Market Analysis and Forecasts, 2015–2025
            4.5.3. Market Revenue Projections (US$ Mn)
     4.6. CVD Market - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.9. Market Outlook

5. Global CVD Market Analysis and Forecasts, By Drug Class 
     5.1. Introduction & Definition
     5.2. Key Findings 
     5.4. Market Value Forecast By Drug Class , 2015–2025
            5.4.1. Renin-Angiotensin System Blockers
                     5.4.1.1. ACE Inhibitors
                     5.4.1.2. Angiotensin Receptor Blockers
            5.4.2. Beta Blockers
            5.4.3. Diuretics
            5.4.4. Anti-Clotting Agents
                     5.4.4.1. Anti-Coagulants
                     5.4.4.2. Platelet Aggregation Inhibitors
            5.4.5. Antihyperlipidemics
            5.4.6. Other Antihypertensives
            5.4.7. Calcium Channel Blockers
            5.4.8. Others
     5.5. Market Attractiveness By Drug Class

6. Global CVD Market Analysis and Forecasts, By Indications 
     6.1. Introduction & Definition
     6.2. Key Findings 
     6.4. Market Value Forecast By Indications , 2015–2025
            6.4.1. Hypertension
            6.4.2. Hyperlipidemia
            6.4.3. Coronary Artery Disease
            6.4.4. Peripheral Artery Disease
            6.4.5. Arrhythmia
            6.4.6. Others
     6.5. Market Attractiveness By Indications

7. Global CVD Market Analysis and Forecasts, By Distribution Channel 
     7.1. Introduction & Definition
     7.2. Key Findings 
     7.4. Market Value Forecast By Distribution Channel , 2015–2025
            7.4.1. Hospital Pharmacy
            7.4.2. Retail Pharmacy
            7.4.3. Online Pharmacy
     7.5. Market Attractiveness By Distribution Channel

8. Global CVD Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Market Value Forecast By Region
            8.2.1. North America 
            8.2.2. Europe 
            8.2.3. Asia Pacific 
            8.2.4. Latin America 
            8.2.5. Middle East & Africa 
     8.3. Market Attractiveness By Country/Region

9. North America CVD Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. Market Value Forecast By Drug Class , 2015–2025
            9.2.1. Renin-Angiotensin System Blockers
                     9.2.1.1. ACE Inhibitors
                     9.2.1.2. Angiotensin Receptor Blockers
            9.2.2. Beta Blockers
            9.2.3. Diuretics
            9.2.4. Anti-Clotting Agents
                     9.2.4.1. Anti-Coagulants
                     9.2.4.2. Platelet Aggregation Inhibitors
            9.2.5. Antihyperlipidemics
            9.2.6. Other Antihypertensives
            9.2.7. Calcium Channel Blockers
            9.2.8. Others
     9.3. Market Value Forecast By Indications , 2015–2025
            9.3.1. Hypertension
            9.3.2. Hyperlipidemia
            9.3.3. Coronary Artery Disease
            9.3.4. Peripheral Artery Disease
            9.3.5. Arrhythmia
            9.3.6. Others
     9.4. Market Value Forecast By Distribution Channel , 2015–2025
            9.4.1. Hospital Pharmacy
            9.4.2. Retail Pharmacy
            9.4.3. Online Pharmacy
     9.5. Market Value Forecast By Country , 2015–2025
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Drug Class 
            9.6.2. By Indications 
            9.6.3. By Distribution Channel 
            9.6.4. By Country

10. Europe CVD Market Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
     10.2.Market Value Forecast By Drug Class , 2015–2025
            10.2.1. Renin-Angiotensin System Blockers
                     10.2.1.1. ACE Inhibitors
                     10.2.1.2. Angiotensin Receptor Blockers
            10.2.2. Beta Blockers
            10.2.3. Diuretics
            10.2.4. Anti-Clotting Agents
                     10.2.4.1. Anti-Coagulants
                     10.2.4.2. Platelet Aggregation Inhibitors
            10.2.5. Antihyperlipidemics
            10.2.6. Other Antihypertensives
            10.2.7. Calcium Channel Blockers
            10.2.8. Others
     10.3. Market Value Forecast By Indications , 2015–2025
            10.3.1. Hypertension
            10.3.2. Hyperlipidemia
            10.3.3. Coronary Artery Disease
            10.3.4. Peripheral Artery Disease
            10.3.5. Arrhythmia
            10.3.6. Others
     10.4. Market Value Forecast By Distribution Channel , 2015–2025
            10.4.1. Hospital Pharmacy
            10.4.2. Retail Pharmacy
            10.4.3. Online Pharmacy
     10.5. Market Value Forecast By Country , 2015–2025
            10.5.1. Germany
            10.5.2. U.K.
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe 
     10.6. Market Attractiveness Analysis 
            10.6.1. By Drug Class 
            10.6.2. By Indications 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Asia Pacific CVD Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
     11.2. Market Value Forecast By Drug Class , 2015–2025
            11.2.1. Renin-Angiotensin System Blockers
                     11.2.1.1. ACE Inhibitors
                     11.2.1.2. Angiotensin Receptor Blockers
            11.2.2. Beta Blockers
            11.2.3. Diuretics
            11.2.4. Anti-Clotting Agents
                     11.2.4.1. Anti-Coagulants
                     11.2.4.2. Platelet Aggregation Inhibitors
            11.2.5. Antihyperlipidemics
            11.2.6. Other Antihypertensives
            11.2.7. Calcium Channel Blockers
            11.2.8. Others
     11.3. Market Value Forecast By Indications , 2015–2025
            11.3.1. Hypertension
            11.3.2. Hyperlipidemia
            11.3.3. Coronary Artery Disease
            11.3.4. Peripheral Artery Disease
            11.3.5. Arrhythmia
            11.3.6. Others
     11.4. Market Value Forecast By Distribution Channel , 2015–2025
            11.4.1. Hospital Pharmacy
            11.4.2. Retail Pharmacy
            11.4.3. Online Pharmacy
     11.5. Market Value Forecast By Country , 2015–2025
            11.5.1. Japan
            11.5.2. China
            11.5.3. India
            11.5.4. Australia & New Zealand 
            11.5.5. Rest of Asia Pacific 
     11.6. Market Attractiveness Analysis 
            11.6.1. By Drug Class 
            11.6.2. By Indications 
            11.6.3. By Distribution Channel 
            11.6.4. By Country

12. Latin America CVD Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
     12.2. Market Value Forecast By Drug Class , 2015–2025
            12.2.1. Renin-Angiotensin System Blockers
                     12.2.1.1. ACE Inhibitors
                     12.2.1.2. Angiotensin Receptor Blockers
            12.2.2. Beta Blockers
            12.2.3. Diuretics
            12.2.4. Anti-Clotting Agents
                     12.2.4.1. Anti-Coagulants
                     12.2.4.2. Platelet Aggregation Inhibitors
            12.2.5. Antihyperlipidemics
            12.2.6. Other Antihypertensives
            12.2.7. Calcium Channel Blockers
            12.2.8. Others
     12.3. Market Value Forecast By Indications , 2015–2025
            12.3.1. Hypertension
            12.3.2. Hyperlipidemia
            12.3.3. Coronary Artery Disease
            12.3.4. Peripheral Artery Disease
            12.3.5. Arrhythmia
            12.3.6. Others
     12.4. Market Value Forecast By Distribution Channel , 2015–2025
            12.4.1. Hospital Pharmacy
            12.4.2. Retail Pharmacy
            12.4.3. Online Pharmacy
     12.5. Market Value Forecast By Country , 2015–2025
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis 
            12.6.1. By Drug Class 
            12.6.2. By Indications 
            12.6.3. By Distribution Channel 
            12.6.4. By Country

13. Middle East & Africa CVD Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Market Value Forecast By Drug Class , 2015–2025
            13.2.1. Renin-Angiotensin System Blockers
                     13.2.1.1. ACE Inhibitors
                     13.2.1.2. Angiotensin Receptor Blockers
            13.2.2. Beta Blockers
            13.2.3. Diuretics
            13.2.4. Anti-Clotting Agents
                     13.2.4.1. Anti-Coagulants
                     13.2.4.2. Platelet Aggregation Inhibitors
            13.2.5. Antihyperlipidemics
            13.2.6. Other Antihypertensives
            13.2.7. Calcium Channel Blockers
            13.2.8. Others
     13.3. Market Value Forecast By Indications , 2015–2025
            13.3.1. Hypertension
            13.3.2. Hyperlipidemia
            13.3.3. Coronary Artery Disease
            13.3.4. Peripheral Artery Disease
            13.3.5. Arrhythmia
            13.3.6. Others
     13.4. Market Value Forecast By Distribution Channel , 2015–2025
            13.4.1. Hospital Pharmacy
            13.4.2. Retail Pharmacy
            13.4.3. Online Pharmacy
     13.5. Market Value Forecast By Country , 2015–2025
            13.5.1. South Africa
            13.5.2. GCC Region 
            13.5.3. Israel 
            13.5.4. Rest of Middle East and Africa 
     13.6. Market Attractiveness Analysis 
            13.6.1. By Drug Class 
            13.6.2. By Indications 
            13.6.3. By Distribution Channel 
            13.6.4. By Country

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis By Company (2016)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. AstraZeneca
                     14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.1.2. Financial Overview
                     14.3.1.3. Product Portfolio
                     14.3.1.4. SWOT Analysis 
                     14.3.1.5. Strategic Overview
            14.3.2. Pfizer Inc.
                     14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.2.2. Financial Overview
                     14.3.2.3. Product Portfolio
                     14.3.2.4. SWOT Analysis 
                     14.3.2.5. Strategic Overview
            14.3.3. Novartis AG
                     14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.3.2. Financial Overview
                     14.3.3.3. Product Portfolio
                     14.3.3.4. SWOT Analysis 
                     14.3.3.5. Strategic Overview
            14.3.4. Merck & Co. Inc.
                     14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.4.2. Financial Overview
                     14.3.4.3. Product Portfolio
                     14.3.4.4. SWOT Analysis 
                     14.3.4.5. Strategic Overview
            14.3.5. Bristol-Myers Squibb Company
                     14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.5.2. Financial Overview
                     14.3.5.3. Product Portfolio
                     14.3.5.4. SWOT Analysis 
                     14.3.5.5. Strategic Overview
            14.3.6. Bayer AG
                     14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.6.2. Financial Overview
                     14.3.6.3. Product Portfolio
                     14.3.6.4. SWOT Analysis 
                     14.3.6.5. Strategic Overview
            14.3.7. Sanofi
                     14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.7.2. Financial Overview
                     14.3.7.3. Product Portfolio
                     14.3.7.4. SWOT Analysis 
                     14.3.7.5. Strategic Overview
            14.3.8. Boehringer Ingelheim GmbH
                     14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.8.2. Financial Overview
                     14.3.8.3. Product Portfolio
                     14.3.8.4. SWOT Analysis 
                     14.3.8.5. Strategic Overview
            14.3.9. F. Hoffmann-La Roche Ltd.
                     14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.9.2. Financial Overview
                     14.3.9.3. Product Portfolio
                     14.3.9.4. SWOT Analysis 
                     14.3.9.5. Strategic Overview
            14.3.10. Abbott Laboratories
                     14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.10.2. Financial Overview
                     14.3.10.3. Product Portfolio
                     14.3.10.4. SWOT Analysis 
                     14.3.10.5. Strategic Overview
            14.3.11. Gilead Sciences, Inc.
                     14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.11.2. Financial Overview
                     14.3.11.3. Product Portfolio
                     14.3.11.4. SWOT Analysis 
                     14.3.11.5. Strategic Overview
            14.3.12. Johnson & Johnson
                     14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.12.2. Financial Overview
                     14.3.12.3. Product Portfolio
                     14.3.12.4. SWOT Analysis 
                     14.3.12.5. Strategic Overview
            14.3.13. Astellas Pharma, Inc.
                     14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.13.2. Financial Overview
                     14.3.13.3. Product Portfolio
                     14.3.13.4. SWOT Analysis 
                     14.3.13.5. Strategic Overview
            14.3.14. Eli Lilly and Company
                     14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.14.2. Financial Overview
                     14.3.14.3. Product Portfolio
                     14.3.14.4. SWOT Analysis 
                     14.3.14.5. Strategic Overview
            14.3.15. Otsuka Holdings Co., Ltd.
                     14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.15.2. Financial Overview
                     14.3.15.3. Product Portfolio
                     14.3.15.4. SWOT Analysis 
                     14.3.15.5. Strategic Overview
            14.3.16. Takeda Pharmaceuticals Company Limited
                     14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.16.2. Financial Overview
                     14.3.16.3. Product Portfolio
                     14.3.16.4. SWOT Analysis 
                     14.3.16.5. Strategic Overview

List of Tables 

Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class – Renin-Angiotensin System Blockers, 2015–2025
Table 03: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class – Anti-Clotting Agents, 2015–2025
Table 04: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 05: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 06: Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Region, 2017–2025
Table 07: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 08: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 09: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 10: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 11: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 12: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 13: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 14: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 16: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 17: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 18: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 19: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 20: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 21: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 22: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 23: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 24: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 25: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 26: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 27: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 28: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 29: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 30: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 31: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 32: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 33: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
Table 34: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
Table 35: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 36: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 37: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025

List of Figures

Figure 01: Global Cardiovascular Drugs Market Snapshot
Figure 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 03: Global Cardiovascular Market Value Share, by Drug Class (2016)
Figure 04: Global Cardiovascular Market Value Share, by Indication (2016)
Figure 05: Global Cardiovascular Market Value Share, by Distribution Channel (2016)
Figure 07: Global Cardiovascular Market Value Share, by Region (2016)
Figure 06: Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 08: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by RAS Blockers, 2015–2025
Figure 09: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Blockers, 2015–2025
Figure 10: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Diuretics, 2015–2025
Figure 11: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Anti-clotting Agents, 2015–2025
Figure 12: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antihyperlipidemics, 2015–2025
Figure 13: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Other Antihypertensive, 2015–2025
Figure 14: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Calcium Channel Blockers, 2015–2025
Figure 15: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
Figure 16: Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class 2017-2025
Figure 17: Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2017 and 2025
Figure 18: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hypertension, 2015–2025
Figure 19: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hyperlipidemia, 2015–2025
Figure 20: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Coronary Artery Disease, 2015–2025
Figure 21: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Peripheral Vascular Disease, 2015–2025
Figure 22: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antiarrhythmic, 2015–2025
Figure 23: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
Figure 24: Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication 2017-2025
Figure 25: Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 26: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 27: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
Figure 28: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
Figure 29: Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel 2017-2025
Figure 30: Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2016 and 2025
Figure 31: Global Cardiovascular Drugs Market Attractiveness Analysis, by Region
Figure 32: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 33: North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 34: North America Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 35: North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 36: North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 37: North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 38: North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 39: North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 40: North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 41: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 42: Europe Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 43: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 44: Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 45: Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 46: Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 47: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 48: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 49: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 50: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 51: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 52: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 53: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 54: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 55: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 56: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 57: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 58: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 59: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 60: Latin America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 61: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 62: Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 63: Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 64: Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 65: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 66: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 67: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 68: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 69: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
Figure 70: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country
Figure 71: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 72: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
Figure 73: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 74: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
Figure 75: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication
Figure 76: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 77: Global Cardiovascular Drugs Market Share Analysis By Company (2016)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

532

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved